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Selective decontamination of the digestive tract (SDD) has been subject of numerous randomized controlled trials in critically ill
patients. Almost all clinical trials showed SDD to prevent pneumonia. Nevertheless, SDD has remained a controversial strategy.
One reason for why clinicians remained reluctant to implement SDD into daily practice could be that mortality was reduced
in only 2 trials. Another reason could be the heterogeneity of trials of SDD. Indeed, many diﬀerent prophylactic antimicrobial
regimes were tested, and dissimilar diagnostic criteria for pneumonia were applied amongst the trials. This heterogeneity impeded
interpretation and comparison of trial results. Two other hampering factors for implementation of SDD have been concerns over
theriskofantimicrobialresistanceandfearforescalationofcostsassociatedwiththeuseofprophylacticantimicrobials.Thispaper
describes the concept of SDD, summarizes the results of published trials of SDD in mixed medical-surgical intensive care units,
and rationalizes the risk of antimicrobial resistance and rise of costs associated with this potentially life-saving preventive strategy.
1.Introduction
Potentially pathogenic microorganisms such as Gram-
negative bacteria (including Pseudomonas aeruginosa),
Gram-positive bacteria (including Staphylococcus aureus),
and yeasts rapidly colonize stomach and intestines of
critically ill patients [1]. Retrograde colonization of the oral
cavity and throat may occur, and microaspiration into the
lung could eventually result in pneumonia [2]. Prevention
of colonization of oral cavity, throat, stomach, and intestines
could reduce the incidence of respiratory tract infections,
thereby improving outcome of intensive care unit (ICU)
patients.
Selective decontamination of the digestive tract (SDD)
is one strategy to prevent colonization of oral cavity,
throat, stomach, and intestines of ICU patients. Numerous
randomized controlled clinical trials have suggested SDD a
beneﬁcial strategy. Indeed, reductions in the incidence of
pneumonia have been achieved with the use of SDD in
critically ill patients [3]. However, only 2 trials showed SDD
to reduce mortality [4,5].Thismayhavecausedcaregiversto
become indisposed to apply this strategy in daily practice. In
addition, fear for emergence of antimicrobial resistance and
escalation of costs associated with SDD, at least in part, ham-
peredwidespreadimplementationofthispreventivestrategy.
It should be noticed that the concept of colonization
and infection as presented by Stoutenbeek and van Saene
concerned trauma patients. It can be questioned whether
this concept holds true for other ICU patients. Indeed, these
patients are older, have signiﬁcant comorbidities, and are
frequently on antibiotics already at or before admission to
the ICU.
We here describe the concept of SDD. We summarize
the numerous clinical trials of SDD, focusing on trials
applying the original SDD strategy in mixed medical-
surgical ICUs and having pneumonia and/or mortality as
a primary endpoint. Concerns over bacterial resistance and
costs associated with SDD are discussed and rationalized.2 Critical Care Research and Practice
2.ICU-RelatedInfections
2.1. Incidence and Outcome. ICU-related infections, in par-
ticular pneumonia, constitute a major problem during
critical illness [6, 7]. Up to 50% of critically ill patients
develop pneumonia [8]. When critically ill patients develop
pneumonia, ICU and hospital mortality may double [9].
In accordance, patients with pneumonia need mechanical
ventilation for a longer period of time and have a prolonged
stay in ICU and hospital [10, 11]. Consequently, costs rise
when pneumonia develops [12–14].
2.2. Primary and Secondary Endogenous versus Exogenous
Infections. ICU-related infections can be classiﬁed into pri-
mary endogenous, secondary endogenous, and exogenous
infections [15].
Primary endogenous infections are caused by pathogens
carried in throat, stomach, and/or intestines of patient on
ICU-admission. They occur generally within one week after
admission and can be prevented by parenteral antibiotics
administered directly after admission to the ICU.
Secondary endogenous infections may also occur soon
after admission to the ICU. Contrary to primary endogenous
infections, pathogens involved with secondary endogenous
infections are not carried in throat, stomach, and/or
intestines on admission but acquired during stay in ICU,
and mostly from other patients via the hands of caregivers.
Most of these infections could be banned if colonization is
prevented.
Exogenousinfectionscanoccuratanytimeduringstayin
ICU and occur when exogenous pathogens are accidentally
introduced into a sterile internal organ without previous
carriage.
2.3. Pathogenic Microorganisms of ICU-Related Infections.
Micro-organisms diﬀer in their pathogenicity. For example,
fast majorities of ICU patients carry Enterococcus spp. in
high concentrations in the intestines; infections caused by
thesemicroorganismsarerare.Conversely,30%–40%ofICU
patients who carry aerobic Gram-negative bacteria (includ-
ing P. aeruginosa and Klebsiella spp.) in the oral cavity, throat
or intestines develop an infection caused by these organisms.
The pathogenicity can be expressed in the Intrinsic
Pathogenicity Index (IPI) [16]. IPI is number of patients
infected by species x/number of patients carrying species
× in throat or intestines. The range of IPI is from 0
to 1. Carriage of a microorganism with an IPI close
to 0 will seldom be followed by an infection. Carriage
of a microorganism with an IPI close to 1 will almost
always be followed by an infection. According to the IPI,
microorganismscanbedividedinlow,potentiallyandhighly
pathogenic microorganisms (Table 1). Prevention of carriage
with pathogens with an IPI close to 1 is thought to beneﬁt
ICU patients.
3. Prevention of ICU-Related Infections
3.1.SelectiveDecontaminationoftheDigestiveTract. Multiple
strategies to reduce the incidence of respiratory infections in
ICU patients have been evaluated, including SDD. Van der
Waaij et al. were the ﬁrst to describe the concept of SDD
in 1971 [17]. The concept of SDD is based on colonization
resistance—the intact, anaerobic intestinal ﬂora is protective
against secondary colonization with Gram-negative aerobic
bacteria. Disturbance or loss of this anaerobic ﬂora leads
to increased colonization and increased risk of infection
with facultative aerobic bacteria. SDD should prevent col-
onization with aerobic Gram-negative bacteria and other
pathogens, without disrupting the anaerobic ﬂora with the
aim to reduce the incidence of secondary infections.
3.2. Components of SDD. SDD classically consists of 4
components [18]( Figure 1):
(I) selective eradication of pathogenic microorganisms
in the oral cavity and decontamination of the
stomach and intestines by local administration of
nonabsorbable antimicrobial agents—the ﬁrst is
reached by application of a paste, gel, or lozenge to
the oropharynx, the second by administration of a
suspension through a nasogastric tube;
(II) systemic prophylaxis by a short course of an intra-
venous antimicrobial agent—to prevent respiratory
infectionsthatmayoccurduringtheICUstay,caused
by commensal respiratory ﬂora;
(III) high levels of hygiene to prevent cross-contamina-
tion;
(IV) surveillancecultures(regularculturesof throatswabs
and feces/rectum) to monitor the eﬀectiveness of
SDD.
It has been suggested that failure to apply this complete 4-
component model reduces the eﬀectiveness of SDD [19],
although this has neither been tested nor proven.
4. Studiesof SDD
4.1. Search Strategy. We identiﬁed relevant publications on
SDD by searching the PubMed, EMBASE, and Cochrane
Library databases using the following terms or MeSH subject
heading: [intensive care], [critical care], [critical illness],
[critical mortality], [infections], [pneumonia], [infection
control], [selective digestive decontamination], [antibiotic
prophylaxis], [antibacterial agents/therapeutic use], [bac-
terial infections/prevention and control], [drug resistance
(microbial/bacterial)], [costs and cost analysis], [cost–
beneﬁt analysis], [cost-eﬀectiveness analysis], [economics],
[drug costs], and [health care costs]. Reference lists from
identiﬁed citations and relevant review articles were hand
searched for additional potentially relevant publications and
abstracts.
With this search strategy, trials analyzing the oral decon-
tamination strategy were also found, but subsequently we
focused on the complete SDD regimen. We also restricted
our search to trials performed in mixed medical-surgical
ICUs and to studies that had pneumonia and/or mortality as
the primary endpoint. Adjacent to this, we looked for studiesCritical Care Research and Practice 3
Table 1: Pathogenicity of microorganisms.
Site of carriage Micro-organisms involved Flora
Low pathogenic microorganisms; IPI = 0.01
Throat
Streptococcus viridans
Normal
Veillonella spp.
Peptostreptococci
Gut
Bacteroides spp.
Clostridium spp.
Enterococcus spp
Escherichia Coli
Vagina Indigenous ﬂora
Skin Coagulase-negative Staphylococci
Potentially pathogenic microorganisms; IPI = 0.3–0.6
Normal
“Community” PPM
Throat
Streptococcus pneumoniae
Hemophilus. Inﬂuenzae
Moraxella catarrhalis
Staphylococcus aureus
Candida spp.
Gut
Escherichia coli
Staphylococcus aureus
Candida spp.
“Hospital” PPM
Throat and gut
Klebsiella spp.
Abnormal
Proteus spp.
Morganella spp.
Enterobacter spp.
Citrobacter spp.
Serratia spp.
Pseudomonas aeruginosa
Acinetobacter spp.
Multiresistant Staphylococcus aureus
Highly pathogenic microorganisms; IPI = 0.9–1.0
“Epidemic” microorganisms
Throat Neisseria meningitides Abnormal
Gut Salmonella spp.
See text for details.
thatfocusedonantimicrobialresistanceinducedbySDDand
studies that analyzed costs of SDD treatment.
4.2. Search Results. The search yielded 336 manuscripts of
potential interest. Studies that were performed in speciﬁc
subgroups of ICU-patients, such as neurosurgical patients,
liver transplant patients, burn patients, trauma patients,
patients with severe pancreatitis, and patients after open-
heart surgery, after gastrectomy or after oesophageal resec-
tion, were excluded. We also excluded studies of SDD in the
pediatric ICU setting. We subsequently focused on mortality
and pneumonia, antimicrobial resistance, and costs. This
left us with 20 publications on trials (Table 2), and 15
meta-analyses (Table 3). addition, our search yielded several
publications dealing with antimicrobial resistance (Table 4)
and costs of SDD, respectively.
4.3. Study Heterogeneity. Although we focused on trials
applying the classical 4-component SDD, studies remained
heterogenic.
Diﬀerent methods of randomization were used, for
example inclusion per time period or per ICU. There was
also great variation in the number of patients included in the
retrieved trials.
Second, there was great diversity in used prophylactic
antimicrobials. In the original design, SDD consisted of
locally applied polymyxin E, tobramycin, and amphotericin
Bplussystemicallyappliedcefotaxim[74].Inonetriallocally4 Critical Care Research and Practice
I
III IV
II
-1: application of a paste, gel or
lozenge to the oropharynx
-2: administration of a suspension
through a nasogastrictube
Systemic prophylaxis by a
short course of an intravenous
antimicrobial agent
High levels of hygiene
Surveillance cultures:
-regular cultures of throat
swabs and faeces/rectum
Local administration of
nonabsorbable antimicrobial agents:
Figure 1: The 4 components of the original SDD regimen.
applied amphotericin B was replaced by nystatin [27]. In
other trials tobramyein was replaced by a quinolone [4, 23,
75], gentamicin [66, 76], or neomycin [27, 34]. In many
trials, cefotaxim was replaced by another antimicrobial, such
as ceftazidime [30], ceftriaxone [77], ciproﬂoxacin [56, 75],
oﬂoxacin [33], or trimethoprim [4].
Third, criteria for pneumonia were very diverse. Indeed,
clinical, radiological, and microbial criteria versus bron-
choscopic techniques with quantitative cultures were used.
Consequently, the incidence of VAP ranged from as low as
less than 10% to as high as 85%. Also, great variation in the
mortality of the control group was seen in the diﬀerent trials,
making comparison of studies more diﬃcult.
5. The Effect of SDD on the Incidence of
Pneumonia andMortality
With the exception of 3 trials [25, 28, 31], a reduction of
the incidence of pneumonia was seen with the use of SDD
(Table 2). Reductions were larger in trials that used more
loose criteria for pneumonia. It can be argued that in trials
that used only clinical and/or radiologic criteria with or
without positive cultures of tracheal secretions the reduction
in respiratory tract infections was in fact a reduction in
purulent bronchitis and not a reduction in pneumonia per
se [3]. All meta-analyses demonstrated a reduction of the
incidence of pneumonia with the use of SDD (Table 3).
There were only 2 small studies that demonstrated a
reduction of mortality with the use of SDD [4, 5]. Notably,
most studies were too small to show a signiﬁcant eﬀect of
SDD on mortality (Table 2). Two recently published well-
powered trials also show SDD to reduce mortality of ICU
patients [36, 37]. With the exception of 1 meta-analysis [38],
reduced mortality rates of ICU patients were seen with the
use of SDD (Table 3).
6. Effects of SDD on MicrobialResistance
One concern with prophylactic use of antimicrobial agents
is the risk of the emergence of resistant pathogens [78, 79].
Notably, in most trials colonization with resistant bacteria
or an increase of superinfections was not reported (Table 4).
One trial that speciﬁcally addressed the issue of microbial
resistance found that resistance rates were actually higher in
the control population than in the SDD-treated population
[36]. In addition, a reduction in the incidence of multiresis-
tant Klebsiella spp. with SDD use was seen in 3 other trials
[65, 80, 81].
However, more recently it was shown that SDD was
associated with a gradual increase of rates of ceftazidime-
resistantGram-negativebacteriaintherespiratorytract[72].
The rate of resistant Gram-negative bacteria in the gastroin-
testinal tract signiﬁcantly increased after discontinuation of
SDD [72].
SDD may promote colonization with Gram-positive
bacteria. The rate of colonization with Gram-positive strains
was signiﬁcantly higher, and more cases of Gram-positive
bacteremia occurred in SDD-treated patients [33, 34].
Two meta-analyses showed that resistance against SDD
antimicrobials is not emerging with long-term use [43,
50]. Use of SDD was even associated with a lower rate
of colonization as well as infection with resistant Gram-
negative bacteria [34, 65, 82].
Additional research is mandatory to determine whether
SDD is a safe strategy with respect to the risk of emergence of
antimicrobial resistance, especially in countries with higherCritical Care Research and Practice 5
Table 2: Incidence and relative risks of pneumonia and mortality in trials of SDD in mixed medical-surgical ICUs.
Publication Year N Incidence of pneumonia (%) ICU Mortality (%)
SDD versus control (RR [95% conﬁdence interval])
Ledingham [20] 1988 324 3 versus 9%, P = .006 24 versus 24%, ns
Ulrich [4] 1989 100 6 versus 44%, P<. 00001 31 versus 54%, P<. 02
(0.28 [0.13–0.59]) (0.69 [0.47–1.02])
Godard [21] 1990 181 2 versus 15%, P<. 05 12 versus 18%, ns
McClelland [22] 1990 27 7 versus 50%, P<. 05 60 versus 58%, ns
Aerdts [23] 1991 56 6 versus 62%, P = .0001 12 versus 10%, ns
(0.09 [0.01–0.60]) (0,71 [0.25–2.02])
Blair [24] 1991 256 48 versus 82%, P = .002 15 versus 19%, ns
(0.33 [0.18–0.62]) (0.17 [0.49 – 1.28])
Finch [25] 1991 49 0.69 [0.23–2.01], ns 1.56 [0.88–2.77], ns
Gaussorgues [26] 1991 118 N.A. 1.00 [0.69–1.44], ns
Cockerill [27] 1992 150 5 versus 16%, P = .03 11 versus 19%, ns
0.33 [0.11–0.99] 0.69 [0.34–1.38]
Hammond [28] 1992 239 26 versus 34%, P = .22 12 versus 12%, ns
0.82 [0.51–1.34] 1.08 [0.70–1.67]
Jacobs [29] 1992 91 0 versus 9%, ns 39 versus 53%, ns
0.13 [0.02–0.95] 0.62 [0.37–1.05]
Rocha [5] 1992 101 15 versus 46%, P<. 001 21 versus 44%, P<. 05
0.32 [0.15–0.68] 0.70 [0.49–1.02]
Winter [30] 1992 183 3 versus 18%, P<. 05 36 versus 43%, ns
0.18 [0.05–0.59] 0.83 [0.58–1.19]
Ferrer [31] 1994 80 18 versus 24%, ns 31 versus 27%, ns
0.70 [0.33–1.46] 1.21 [0.63–2.34]
Palomar [32] 1997 129 17 versus 50%, P = .005 24 versus 31%, ns
0,39 [0,21–0,73] 0,98 [0,52–1,84]
Verwaest [33] 1997 440 9 versus 18%, P = .026 18 versus 17%, ns
0.53 [0.34–0.89] 1,17 [0.81–1.71]
S´ anchez-Garc´ ıa [34] 1998 271 11 versus 29%, P<. 001 39 versus 47%, ns
0.57 [0.40–0.81] 0.84 [0.63–1.11]
Parra Moreno [35] 2002 306 5 versus 20%, P< ,0001 N.A.
0.30 [0.16–0.53]
De Jonge [36] 2003 934 N.A. 15 versus 23%, P = .002
0.65 [0.49–0.85]
De Smet [37] 2009 4035 N.A. 3.5% points absolute reduction, P = .02
0.81 [0.69–0.94]
N: number of patients; ns: not signiﬁcant; N.A.: not available.
endemicity of multidrug-resistant pathogens, because with
the available evidence this risk cannot completely be denied.
7. Costs of SDD
Several studies compared costs of antimicrobial therapies
between the SDD strategy and the control strategy, though
in all these trials cost was only a secondary endpoint.
Costs have been calculated in diﬀerent ways. One trial
showed no diﬀerences in costs between the SDD strategy
and the control strategy [67]. Studies that used cefotaxime
showed a reduction of costs. Two other trials, however,
showed higher costs with SDD when a quinolone was given
for systemic prophylaxis [33, 75].
Four trials analyzed total ICU costs per survivor [5, 61,
77, 83]. These trials showed a reduction of costs with the use
of SDD, which was the result of reductions in length of stay
and reduced use of systemic antibiotics.
8. Discussion
The ﬁndings of our review of the literature can be summa-
rizedasfollows:(I)numeroustrialsofSDDshowareduction
of the incidence of pneumonia with this preventive strategy,6 Critical Care Research and Practice
Table 3: Odds ratios for pneumonia and mortality in meta-analyses of trials of SDD.
Publication Year n/N Pneumonia Mortality
OR [95% conﬁdence interval]
Van den Broucke-Grauls [38] 1991 6/491 0.12 [0.08–0.19] 0.70 [0.45–1.09]
SDD Group [39] 1993 22/4142 0,37 [0.31–0.43] 0.90 [0.79–1.04]
Heyland [40] 1994 24/3312 0.46 [0.39–0.56] 0.87 [0,79–0.97]
Kollef [41] 1994 16/2270 0.15 [0.12–0.17] 0.02 [−0.02–0.05]
Hurley [42] 1995 26/3768 0.35 [0.30–0.42] 0.86 [0.74–0.99]
D’Amico [43] 1998 16/3361 0.35 [0.29–0.41] 0.80 [0.69–0.93]
1999 21/N.A. N.A. 0.70 [0.52–0.93]a
Nathens [44] 0.91 [0.71–1.18]b
Liberati [45] 2000 16/3361 0.35 [0,29–0.41] 0.80 [0.69–0.93]
Redman [46] 2001 N.A. 0.36 [0.28–0.46] N.A.
Liberati [47] 2004 36/6922 0.35 [0.29–0.41] 0.78 [0.68–0.89]
Silvestri [48] 2007 51/8065 N.A. 0.80 [0.69–0.94]
Silvestri [49] 2008 54/9473 0.11 [0.06–0.20] N.A.
Silvestri [50] 2009 21/4902 N.A. 0.71 [0.61–0.82]
Liberati [51] 2009 36/6914 0.28 [0.20–0.38] 0.75 [0.65–0.87]
asurgical patients; bmedical patients; n/N: number of trails/patients; OR: odds ratio; N.A.: not available.
Table 4: SDD and the emergence of antimicrobial resistance, in areas with high and low endemicity.
Endemicity Main ﬁndings
MRSA
High Increase of colonization with MRSA [28, 31, 33, 52–55]
Low No increase of colonization with MRSA [36, 56, 57]
VRE
High No increase of VRE infection rates [58, 59]; no increase of VRE infection rates when enteral vancomycin is added
[26, 56, 60–64]
Low No increase of VRE carriage [36]; increase of VRE isolates [57]
AGNB
High
Decrease of multiresistant AGNB [54, 65]; lower incidence of carriage and infections with antibiotic resistant
Gram-negative bacteria [36, 66–69]; no increase in prevalence of beta lactam- or aminoglycoside-resistant
Gram-negative rods [57, 70]; increased antimicrobial resistance [5, 33, 71]
Low
Increased intestinal colonization with Gram-negative bacteria resistant to ceftazidime, tobramycin, or
ciproﬂoxacin—discontinuation of SDD results in a rebound eﬀect of ceftazidime resistant bacteria in the intestinal
tract [72]; SDD increased the number of infections caused by multiresistant bacteria [73]
MRSA: methicillin-resistant Staphylococcus aureus, VRE: vancomycin-resistant Enterococci and AGNB: aerobic Gram-negative bacteria.
(II)well-poweredtrialsofSDDshowareductionofmortality
with SDD, (III) although SDD is associated with induction
of antimicrobial resistance in some studies, it certainly was
not a problem in all trials, and (IV) SDD seems to be a cost-
eﬀective strategy.
Preventive measures against pneumonia in critically ill
patients include, but may not be restricted to, early wean-
ing from mechanical ventilation, hand hygiene, aspiration
precautions, and prevention of contamination—at times
summarized with the acronym “WHAP” [84]. It has been
demonstrated that an educational initiative on WHAP,
directed at respiratory care practitioners and ICU-nurses,
was associated with decreases in VAP incidence rates of up
to 61% [84]. One of the problems with the interpretation
of the trials of SDD is that it is uncertain whether the
caregivers complied with these prevention strategies. Indeed,
only “high levels of hygiene” is a component of SDD.
Interpretation and comparison of the results of trials of
SDD are complicated by the many dissimilarities amongst
SDD regimens that were applied. We tried to solve this issue
by focusing on studies that investigated the eﬀect of the
classical SDD regimen, applying all 4 components thought
to be important for its eﬃcacy [18]. Nevertheless, large
diﬀerencesremainedpresent.Interpretationandcomparison
of the results of trials of SDD are also complicated by
the diﬀerence in quality of the individual studies. For
instance, large variation in the incidence of pneumonia
was seen, due to diﬀerence in the way pneumonia was
diagnosed. The incidence of pneumonia in studies that used
bronchoscopic techniques with quantitative cultures wasCritical Care Research and Practice 7
half of that in studies made the diagnosis of pneumonia
on clinical and radiological criteria. Nevertheless, since all
studies showed a positive eﬀect of SDD with respect to the
rate of pneumonia, we consider the evidence for SDD as an
eﬀective prophylactic strategy suﬃcient. Thereby it can be
questioned if it is necessary to give the “full” protocol, with
intestinal decontamination and systemic cefotaxime. In the
light of the recently published work by de Smet et al. the role
of intestinal decontamination and of systemic cefotaxime
seems to be questionable [37].
The fast majority of trials of SDD showed no eﬀect on
mortality. It should be noted, however, that most studies
were underpowered to show any eﬀect on mortality. The last
2 trials of SDD, however, were adequately powered [36, 37].
Since these 2 trials showed SDD to reduce mortality of ICU
patients, we also consider the evidence for SDD as a life-
saving strategy suﬃcient.
It can be questioned if SDD should be given to all ICU
patients or restricted to selected groups. We have solely
focused on the eﬀect of SDD in patients in mixed medical-
surgical ICUs.
The emergence of antimicrobial resistance with SDD has
been the subject of numerous hot debates [85–87]. It has
been argued that the use of SDD would promote the growth
of resistant bacteria. In theory, this is a potential adverse
eﬀect of SDD treatment, but in low antibiotic resistance
endemic areas this seems not to be a problem. The 2 trials
that investigated resistance were performed in The Nether-
lands, a country with the lowest use of outpatient antibiotics,
generally a narrower spectrum antibiotic for hospitalized
patients, a low incidence of methicillin-resistant S. aureus,
vancomycin-resistant Enterococci (VRE) other multidrug-
resistant pathogens, and extended spectrum b` eta-lactamase
(ESBL) producing pathogens [88, 89]. This situation is
markedly diﬀerent from other centers across the world.
BecauseSDDisnotactiveagainstresistantGram-positive
bacteria, it may promote colonization with bacteria such
as S. Aureus,a n dE. faecalis and it can lead to infections
with these bacteria in critically ill patients [90–92]. Patients’
illness causes conversion of carriage of normal to abnormal
ﬂora. Most ICU patients have bacterial overgrowth. The
increased spontaneous mutations lead to polyclonality and
antimicrobial resistance [93]. In this way, treatment with
SDD could promote gut overgrowth of intrinsically resistant
bacteria, such as MRSA and VRE, although with endemicity
no increase has been found [36, 94, 95]. However, it cannot
be excluded that in countries where VRE is endemic, SDD
can have a negative eﬀect on VRE. On the other hand, the
reduced prescription of systemic-broad spectrum antibiotics
in SDD-treated patients may also lead to decreased inci-
dence of VRE. Although SDD does exert selection pressure
on plasmid-mediated ESBL, emergence of ESBL-producing
bacteria due to SDD has not been found.
SDD seems a safe strategy with regard to the emergence
of antibiotic resistance in low antibiotic resistance endemic
areas, but with the available evidence, we cannot say that
SDD is also a safe strategy in high endemicity areas. We
should consider giving SDD only in low endemic areas
till results in high endemic areas are available. Additional
research is also mandatory to determine what to do when
resistant pathogens do emerge.
Another concern with SDD is the cost associated with
this preventive strategy. Costs of SDD have been calculated
in several studies, but most of these were not designed to
analyze cost-eﬀectiveness. The absence of studies on costs
andcost-eﬀectivenessis remarkable.Itcouldbethataproper
economic analysis in the ICU setting is diﬃcult to perform,
because it is hard to quantify the relative contribution of
a single strategy. For example, the price of intravenous
antibiotics can vary widely between hospitals, because the
price is dependent on negotiations between local pharmacy
and manufacturers.
The most important cost component associated with
SDD is the cost of antibiotics. As the aim of SDD is to reduce
in ICU infections, including pneumonia, a reduction in total
antibiotic use can be expected. Overall hospital costs may
be lower, in part due to the decrease rate of pneumonia.
Development of pneumonia is associated with up to 5
extra days of ICU treatment. Prevention of pneumonia
substantially decreases the length of ICU stay and thus
reduces costs per patient.
9. Conclusion
Numerous randomized controlled trials have shown that
SDD reduces the incidence of pneumonia. Two recently pub-
lishedwell-poweredtrialsalsoshowSDDtoreducemortality
of ICU patients. SDD can be associated with induction of
antimicrobial resistance, but this seems not to be a clinical
problem, at least not in countries with low endemicity.
Finally, SDD seems to be a cost-eﬀective strategy. Based on
these ﬁndings, we favor the use of SDD in ICU patients.
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